We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) incurred an adjusted loss of $1.57 per share in the fourth quarter of 2019, wider than the year-ago adjusted loss of 85 cents per share. The wider year-over-year loss can be primarily attributed to a significant rise in operating expenses.
Notably, the adjusted figure excludes one-time items, depreciation & amortization expenses, interest expenses, income tax benefit, stock-based compensation expense and other items. Including all these items, the company incurred a loss of $3.16 per share compared with a loss of $2.05 in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of $1.91.
Meanwhile, Sarepta’s Exondys 51 — approved for treating Duchenne muscular dystrophy (“DMD”) — continued with its strong performance. The company derived revenues solely from the sale of Exondys 51. Sarepta recorded total revenues of $100.1 million, up 18.6% year over year. However, revenues missed the Zacks Consensus Estimate of $100.25 million.
Shares of Sarepta have declined 25.1% in the past year compared with the industry’s decrease of 9.3%.
Operating Expenses
Adjusted research and development (R&D) expenses totaled $135.4 million in the fourth quarter, up 75.8% year over year. The increase was primarily due to increased clinical activities and initiation of certain post-market studies for Exondys 51.
Adjusted selling, general & administrative (SG&A) expenses were $65.8 million, up 24.4% year over year. Higher costs related to the global commercial expansion of its products and increased personnel expenses increased SG&A expenses.
Full-Year Results
Sarepta reported full year revenues of $380.8 million, up 26.5% compared to year-ago period. Adjusted loss in the period was $4.30 per share compared to $2.14 per share in year-ago period. The significant increase in loss was mainly due to higher operating expenses.
2020 Outlook
Sarepta provided sales guidance for its key marketed drug, Exondys 51, for 2020. It expects the drug to generate $420 million to $430 million in sales. The launch of Vyondys 53 is in initial stage and hence the company plans to provide guidance on its sales later this year.
Pipeline Update
In December 2019, Sarepta’s second DMD drug, Vyondys 53 (golodirsen), received accelerated approval for treating patients with confirmed mutation amenable to exon 53 skipping. The company launched the drug in the same month. Currently, it is conducting a confirmatory study — ESSENCE — to gain continued approval for the drug.
The company has initiated a rolling submission of a new drug application seeking approval for its third exon-skipping DMD product, casimersen. It expects the submission to be completed in the second quarter of 2020.
Sarepta is progressing well with the development of the micro-dystrophin gene therapy candidate, SRP-9001, in a phase II study in DMD patients.
In February 2020, the company closed the previously announced licensing agreement with Roche (RHHBY - Free Report) related to commercialization of Sarepta’s lead gene therapy candidate, SRP-9001, as DMD therapy in ex-U.S. markets, following a potential approval. Sarepta received $1.2 billion in upfront payment from Roche, which includes $750 million in cash and approximately $400 million in exchange of its common stock. The company is also eligible to receive additional $1.7 billion in regulatory and sales milestones along with royalties on net sales. The companies will equally share global development cost for SRP-9001.
Sarepta’s gene therapy pipeline includes candidates targeting LGMD, MPS IIIA and Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited neurological disorder. In November 2019, Sarepta entered into collaboration with privately-held StrideBio, gaining an exclusive license to select gene therapy candidates targeting four CNS disorders, boosting its gene therapy pipeline.
Sarepta Therapeutics, Inc. Price, Consensus and EPS Surprise
Vertex’s earnings per share estimates have moved up from $6.68 to $7.57 for 2020 and from $8.59 to $9.62 for 2021 in the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 21.76%. Share price of the company has increased 22.3% in the past year.
Loss estimates for Clovis narrowed from $4.78 to $4.73 for 2020 and from $3.38 to $3.33 for 2021 in the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
Sarepta Therapeutics, Inc. (SRPT - Free Report) incurred an adjusted loss of $1.57 per share in the fourth quarter of 2019, wider than the year-ago adjusted loss of 85 cents per share. The wider year-over-year loss can be primarily attributed to a significant rise in operating expenses.
Notably, the adjusted figure excludes one-time items, depreciation & amortization expenses, interest expenses, income tax benefit, stock-based compensation expense and other items. Including all these items, the company incurred a loss of $3.16 per share compared with a loss of $2.05 in the year-ago quarter. The Zacks Consensus Estimate was pegged at a loss of $1.91.
Meanwhile, Sarepta’s Exondys 51 — approved for treating Duchenne muscular dystrophy (“DMD”) — continued with its strong performance. The company derived revenues solely from the sale of Exondys 51. Sarepta recorded total revenues of $100.1 million, up 18.6% year over year. However, revenues missed the Zacks Consensus Estimate of $100.25 million.
Shares of Sarepta have declined 25.1% in the past year compared with the industry’s decrease of 9.3%.
Operating Expenses
Adjusted research and development (R&D) expenses totaled $135.4 million in the fourth quarter, up 75.8% year over year. The increase was primarily due to increased clinical activities and initiation of certain post-market studies for Exondys 51.
Adjusted selling, general & administrative (SG&A) expenses were $65.8 million, up 24.4% year over year. Higher costs related to the global commercial expansion of its products and increased personnel expenses increased SG&A expenses.
Full-Year Results
Sarepta reported full year revenues of $380.8 million, up 26.5% compared to year-ago period. Adjusted loss in the period was $4.30 per share compared to $2.14 per share in year-ago period. The significant increase in loss was mainly due to higher operating expenses.
2020 Outlook
Sarepta provided sales guidance for its key marketed drug, Exondys 51, for 2020. It expects the drug to generate $420 million to $430 million in sales. The launch of Vyondys 53 is in initial stage and hence the company plans to provide guidance on its sales later this year.
Pipeline Update
In December 2019, Sarepta’s second DMD drug, Vyondys 53 (golodirsen), received accelerated approval for treating patients with confirmed mutation amenable to exon 53 skipping. The company launched the drug in the same month. Currently, it is conducting a confirmatory study — ESSENCE — to gain continued approval for the drug.
The company has initiated a rolling submission of a new drug application seeking approval for its third exon-skipping DMD product, casimersen. It expects the submission to be completed in the second quarter of 2020.
Sarepta is progressing well with the development of the micro-dystrophin gene therapy candidate, SRP-9001, in a phase II study in DMD patients.
In February 2020, the company closed the previously announced licensing agreement with Roche (RHHBY - Free Report) related to commercialization of Sarepta’s lead gene therapy candidate, SRP-9001, as DMD therapy in ex-U.S. markets, following a potential approval. Sarepta received $1.2 billion in upfront payment from Roche, which includes $750 million in cash and approximately $400 million in exchange of its common stock. The company is also eligible to receive additional $1.7 billion in regulatory and sales milestones along with royalties on net sales. The companies will equally share global development cost for SRP-9001.
Sarepta’s gene therapy pipeline includes candidates targeting LGMD, MPS IIIA and Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited neurological disorder. In November 2019, Sarepta entered into collaboration with privately-held StrideBio, gaining an exclusive license to select gene therapy candidates targeting four CNS disorders, boosting its gene therapy pipeline.
Sarepta Therapeutics, Inc. Price, Consensus and EPS Surprise
Sarepta Therapeutics, Inc. price-consensus-eps-surprise-chart | Sarepta Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Sarepta currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Clovis Oncology . Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings per share estimates have moved up from $6.68 to $7.57 for 2020 and from $8.59 to $9.62 for 2021 in the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 21.76%. Share price of the company has increased 22.3% in the past year.
Loss estimates for Clovis narrowed from $4.78 to $4.73 for 2020 and from $3.38 to $3.33 for 2021 in the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>